ScholarLens Back to search
2016•PubMedRequires access

Using Targeted Inhibitors in the Management of Chronic Lymphocytic Leukemia: Are We There Yet?

Jennifer R. Brown

Open publisher page 0 citations

Abstract

Several critical issues need to be addressed during the next several years if we are to reach the true potential of new agents like ibrutinib, idelalisib, venetoclax, ofatumumab, and obinutuzumab—which conceivably could ultimately cure CLL.

About this research paper

What this paper is about

Several critical issues need to be addressed during the next several years if we are to reach the true potential of new agents like ibrutinib, idelalisib, venetoclax, ofatumumab, and obinutuzumab—which conceivably could ultimately cure CLL.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Several critical issues need to be addressed during the next several years if we are to reach the true potential of new agents like ibrutinib, idelalisib, venetoclax, ofatumumab, and obinutuzumab—which conceivably could ultimately cure CLL.

Key concepts: Ibrutinib, Venetoclax, Ofatumumab, Idelalisib, Obinutuzumab, Chronic lymphocytic leukemia, Medicine, Leukemia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Using Targeted Inhibitors in the Management of Chronic Lymphocytic Leukemia: Are We There Yet? — Research Paper | ScholarLens